Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
CLL
•
Hematology
•
Ophthalmology
How do you manage ocular hemorrhages while on acalabrutinib for CLL?
Related Questions
What are your top takeaways in Hematologic Malignancies from ASH 2024?
How do you manage persistent cytopenias after FCR chemotherapy for treatment of CLL?
In treatment naive CLL without del(17p)/TP53, will the recent interim analysis of fixed duration acalabrutinib plus venetoclax +/- obinutuzumab vs chemoimmunotherapy in the AMPLIFY trial change your practice?
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
How do you decide whether to hold acalabrutinib or zanubrutinib in patients with indolent B-cell lymphoma/leukemias in a perioperative/periprocedural setting?
Can AMPLIFY data be extrapolated to use of other BTKi's in combination with venetoclax or would you only ever use acalabrutinib/venetoclax in first line?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
How do you monitor and manage minimal residual disease (MRD) in patients with core-binding factor (CBF) AML who are in remission post-induction and consolidation therapy?
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?
